philipp eller

So happy and proud to share with you our recent findings! #fightICUdelirium Thanks to all of you. Biomarkers of alcohol abuse potentially predict delirium, delirium duration and mortality in critically ill patients: iScience cell.com/iscience/fullt…

Cytokine adsorption on #ECMO in severe #COVID19? 🦠early initiation did not reduce serum IL-6 + had negative impact on survival 🦠 should not be used during first #ECLS days in #SARSCoV2 patients 🦠uncritical use outside trials cannot be recommended @AlexanderSupady #ELSO2021

"One learnt lesson is clear in 2021: shortcutting science perpetuates ineffective and unsafe treatments."

Published on the very day when I asked for an update during my EuroELSO talk on indications for vvECMO in adults. What a timing😂🤷🏻‍♂️🙏

Our new publication on co-stimulation blockade in glomerulonephritis is online! Congrats especially to @KathiArtinger! Thank's to the lab team and all co-authors! @immunolrosgraz @alehkir @AringerIda @amooslechner @eller_philipp kidney-international.org/article/S0085-…

Reconvalescent plasma treatment for acquired IgG deficiency in haematological cancer patients suffering from COVID 19. Response to "COVID-19 in Persons With Haematological Cancers" pubmed.ncbi.nlm.nih.gov/32528043/

Be aware of side effects of Tocilizumab (IL-6 receptor antagonist) especially in times of Covid activism. Tuberculosis sepsis after tocilizumab treatment recently published by our team! ncbi.nlm.nih.gov/pmc/articles/P…